NeuroSense Therapeutics (NRSNW) Expected to Announce Earnings on Wednesday

NeuroSense Therapeutics (NASDAQ:NRSNW) will likely be announcing its resultson Wednesday, March 25th. Analysts expect the company to announce earnings of ($0.1050) per share for the quarter.

NeuroSense Therapeutics Stock Down 8.7%

NRSNW stock opened at $0.19 on Monday. The business has a 50-day simple moving average of $0.24 and a 200 day simple moving average of $0.32. NeuroSense Therapeutics has a 52 week low of $0.16 and a 52 week high of $1.00.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease.